Co-expression of KLK6 and KLK10 as prognostic factors for survival in pancreatic ductal adenocarcinoma

Rückert, Felix; Hennig, Martin; Cd, Petraki; Wehrum, Diana; Distler, Marius; Denz, Axel; Schröder, M.; Dawelbait, Gihan; Kalthoff, Holger; Hd, Saeger; Diamandis, Eleftherios P.; Pilarsky, Christian; Grützmann, Robert

doi:10.1038/sj.bjc.6604717

Cited by 65 publications

(65 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These results are similar to previous studies that found increased expression of KLK6 in primary pancreatic ductal adenocarcinoma (Ruckert et al, 2008) and salivary gland tumours (Darling et al, 2006), but found no significant association with survival. Kallikreins 6 and 13 are expressed in normal epithelium (Petraki et al, 2001(Petraki et al, , 2003, including the OSE as we have shown here.…”

Section: Discussionsupporting

confidence: 91%

KLK6 and KLK13 predict tumor recurrence in epithelial ovarian carcinoma

et al. 2009

View full text Add to dashboard Cite

BACKGROUND: The human kallikrein-related peptidase family consists of 15 genes. Twelve of these genes are overexpressed in ovarian cancer and may represent potential markers for diagnosis, prognosis, and/or response to treatment. The aim of this study was to determine the prognostic significance of kallikrein-related peptidase 6 (KLK6) and kallikrein-related peptidase 13 (KLK13) in epithelial ovarian cancer by quantifying gene expression levels with tumour pathology and patient survival data. METHODS: Total RNA was isolated from 106 patients diagnosed with primary ovarian cancer, as well as 8 normal ovary controls. Samples were analysed by quantitative real-time PCR for KLK6 and KLK13 expression. Correlation between kallikrein gene expression and clinical characteristics was evaluated with the w 2 -test. Survival analysis was performed using Kaplan -Meier and Cox proportional hazards regression models. RESULTS: Expression levels of both KLK6 and KLK13 mRNA were significantly increased in invasive cancers relative to normal ovaries (P ¼ 0.002 and 0.039 respectively). High KLK6 and KLK13 expression was an indicator of poor prognosis, with patients having a shorter recurrence-free survival (P ¼ 0.002 and 0.027 respectively). High KLK6 expression was also significantly associated with lower overall survival (P ¼ 0.011). When subjected to multivariate analysis, patients with either high KLK6 or KLK13 were 3-and 2.2-fold, respectively, more likely to have a recurrence than patients with low kallikrein expression. CONCLUSION: These data show increased mRNA expression of KLK6 and KLK13 in ovarian cancer compared to normal ovarian tissues. High KLK6 or KLK13 expression in primary ovarian tumours can significantly predict prognosis in terms of recurrence-free survival and overall survival. In all, this study shows KLK6 and KLK13 as potential biomarkers and may be therapeutic targets for treatment of ovarian cancer.

show abstract

Section: Discussionsupporting

confidence: 91%

KLK6 and KLK13 predict tumor recurrence in epithelial ovarian carcinoma

et al. 2009

View full text Add to dashboard Cite

show abstract

“…Both factors have been shown to have an effect on cell motility. Co-expression of kallikrein 6 and kallikrein 10 in native tumor tissue is also correlated with poor survival [17]. We were, therefore, interested to determine if these factors were expressed in our cell lines.…”

Section: Discussionmentioning

confidence: 99%

Five Primary Human Pancreatic Adenocarcinoma Cell Lines Established by the Outgrowth Method

Rückert¹,

Aust²,

Böhme³

et al. 2012

Journal of Surgical Research

View full text Add to dashboard Cite

“…Bcl-2 and lymph node status combined was more powerful than pathologic status alone (27). Further studies, in which no individual marker was prognostic, yielded independently prognostic groups of markers, for example, KLK6 and KLK10 (152).…”

Section: Discussionmentioning

confidence: 99%

Tissue Biomarkers for Prognosis in Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-analysis

Jamieson

Carter

McKay

et al. 2011

Clinical Cancer Research

114

View full text Add to dashboard Cite

Purpose: The management of pancreatic ductal adenocarcinoma (PDAC) continues to present a great challenge particularly with regard to prediction of outcome following pancreaticoduodenectomy. Molecular markers have been extensively investigated by numerous groups with the aim of enhancing prognostication; however, despite hundreds of studies that have sought to assess the potential prognostic value of molecular markers in predicting the clinical course following resection of PDAC, at this time, no molecular marker assay forms part of recommended clinical practice.Experimental Design: We conducted a systematic review and meta-analysis of the published literature for immunohistochemistry-based biomarkers of PDAC outcome. A dual search strategy was applied to the PubMed database on January 6, 2010, to identify cohort studies that reported associations between immunohistochemical biomarker expression and survival outcomes in PDAC, and conformed to the REMARK (REporting recommendations for tumor MARKer prognostic studies) criteria.Results: A total of 103 distinct proteins met all inclusion criteria. Promising markers that emerged for the prediction of overall survival included BAX (HR ¼ 0.31, 95% CI: 0.71-0.56), Bcl-2 (HR ¼ 0.41, 95% CI: 0.27-0.63), survivin (HR ¼ 0.46, 95% CI: 0.29-0.73), Ki-67: (HR ¼ 2.42, 95% CI: 1.87-3.14), COX-2 (HR ¼ 1.39, 95% CI: 1.13-1.71), E-cadherin (HR ¼ 1.80, 95% CI: 1.33-2.42), and S100 calcium-binding proteins, in particular S100A2 (HR ¼ 3.23, 95% CI: 1.58-6.62).Conclusions: We noted that that there was incomplete adherence to the REMARK guidelines with inadequate methodology reporting as well as failure to perform multivariate analysis. Addressing the persistent incomplete adoption of these criteria may eventually result in the incorporation of molecular marker assessment within PDAC management algorithms. Clin Cancer Res; 17(10); 3316-31. Ó2011 AACR.

show abstract

Co-expression of KLK6 and KLK10 as prognostic factors for survival in pancreatic ductal adenocarcinoma

Cited by 65 publications

References 30 publications

KLK6 and KLK13 predict tumor recurrence in epithelial ovarian carcinoma

KLK6 and KLK13 predict tumor recurrence in epithelial ovarian carcinoma

Five Primary Human Pancreatic Adenocarcinoma Cell Lines Established by the Outgrowth Method

Tissue Biomarkers for Prognosis in Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-analysis

Contact Info

Product

Resources

About